Best GLP-1 Providers in South Dakota (2026)

See by medication

Looking for a specific GLP-1? Browse South Dakota providers by drug.

About GLP-1s in South Dakota

South Dakota allows telehealth GLP-1 prescribing. South Dakota Medicaid covers GLP-1s only for type 2 diabetes diagnosis.

• •South Dakota's adult obesity rate is 33.2%
• •SD Medicaid limits GLP-1 coverage to diabetes
• •Telehealth is essential for rural South Dakota residents

Top Cities for GLP-1 Treatment in South Dakota

Telehealth providers ship to all South Dakota addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the South Dakota GLP-1 clinic directory →

GLP-1 Care Access in South Dakota: The Numbers

South Dakota has 67 NPI-registered in-person weight-management clinics across 12 cities — 1 with an obesity-medicine taxonomy, 31 endocrinology, and 35 bariatric — alongside 94 telehealth programs that ship to South Dakota addresses. The cheapest verified ongoing compounded semaglutide price available to South Dakota residents is $79/mo (tirzepatide: $104/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in South Dakota

In Q1 2026, South Dakota Medicaid reimbursed approximately $4,116,127 across 3,936 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in South Dakota cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $199/mo.

For the exact criteria, drug list, and appeal process, read our South Dakota Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in South Dakota

According to CDC data, 33.2% of South Dakota adults have obesity (BMI of 30 or higher). This places South Dakota at #21 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping South Dakota residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions